Key Points A crucial meeting with a regulator didn't seem to go well. It was about a leading pipeline drug being developed by the company. 10 stocks we like better than Replimune Group › On Thursday, Replimune (NASDAQ: REPL) had a crucial meeting with federal regulators regarding one of its leading drug candidates. While the outcome of the event wasn't necessarily negative, it left the future of the drug up in the air, and investors didn't like that uncertainty. As a result, they assertively traded ...